Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Ventilatory Modes01:14

Ventilatory Modes

2.3K
Mechanical ventilators are life-saving devices that support or replace spontaneous breathing. They deliver breaths to patients through varying methods known as ventilator modes. Understanding these modes is critical for healthcare providers managing patients with respiratory failure.
There are three ventilatory modes: full support, partial support, and spontaneous. These are described below.
Full Support Modes
Full support modes include controlled mechanical ventilation, continuous mandatory...
2.3K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

1.3K
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.3K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Mechanical Ventilation III: Noninvasive Ventilation01:23

Mechanical Ventilation III: Noninvasive Ventilation

931
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
931

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaceutical stability of compounded acetylcholine chloride intraocular solution for intracoronary provocative vasospasm testing.

Frontiers in cardiovascular medicine·2026
Same author

Two durable ventricular assist devices in total artificial heart configuration for refractory primary graft dysfunction.

JTCVS techniques·2026
Same author

Engaging Patients and Clinicians With Remote Pulmonary Artery Pressures Monitoring Improves Care: The PROACTIVE-HF Clinical Trial.

JACC. Heart failure·2026
Same author

Lessons Learned from the HVAD Post-Approval Study Registry: Implications for Investigating Future Ventricular Assist Device Technology.

Journal of cardiac failure·2026
Same author

Evaluating Noninferiority in Clinical Trials with a Hierarchical End Point.

NEJM evidence·2026
Same author

Mechanically Reducing Cardiac Preload With the preCARDIA System in Acutely Decompensated Heart Failure.

JACC. Heart failure·2025

Related Experiment Video

Updated: May 2, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.1K

Mechanical circulatory support for right ventricular failure.

Navin K Kapur1, Vikram Paruchuri1, Anand Jagannathan1

  • 1The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.

JACC. Heart Failure
|March 14, 2014
PubMed
Summary

This study shows that centrifugal flow right-ventricular support devices (CF-RVSDs) are clinically feasible for treating right ventricular failure (RVF), improving hemodynamics. Further research is needed to explore their role in percutaneous circulatory support for RVF.

Keywords:
invasive hemodynamicsmechanical circulatory supportright heart failure

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.3K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

8.9K

Related Experiment Videos

Last Updated: May 2, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.1K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.3K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

8.9K

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Medical Devices

Background:

  • Right ventricular failure (RVF) carries a high in-hospital mortality rate.
  • Limited data exist on the efficacy of centrifugal flow right-ventricular support devices (CF-RVSDs) for RVF.

Purpose of the Study:

  • To explore the clinical utility and feasibility of a commercially available centrifugal flow pump as a CF-RVSD in patients with RVF.
  • To assess the hemodynamic impact and in-hospital outcomes of CF-RVSD use in RVF patients.

Main Methods:

  • Retrospective review of data from 46 patients with RVF treated with CF-RVSDs across 8 US tertiary-care hospitals.
  • Data collected from a registry, including indications for CF-RVSD use (e.g., acute myocardial infarction, myocarditis, post-surgery) and implantation route (percutaneous or surgical).

Main Results:

  • No intraprocedural mortality observed; mean support duration was 5.4 days.
  • Significant improvements in mean arterial pressure, right atrial pressure, pulmonary artery systolic pressure, and cardiac index within 48 hours of implantation.
  • Overall in-hospital mortality was 57%, with lower rates in specific conditions like LVAD implantation, chronic left heart failure, and acute MI. Increased age, biventricular failure, and major bleeding were associated with higher mortality.

Conclusions:

  • The use of CF-RVSDs for RVF is clinically feasible and leads to improved hemodynamic status.
  • Registry observations support the need for prospective studies to evaluate percutaneous circulatory support for RVF.